制药工业
医药制造业
质量保证
质量(理念)
过程分析技术
风险分析(工程)
过程(计算)
业务
制造工程
计算机科学
在制品
工程类
生物技术
医学
营销
哲学
操作系统
认识论
药理学
生物
服务(商务)
作者
Nada A. Helal,Ola Elnoweam,Heba A. Eassa,Ahmed Amer,Mohamed A Eltokhy,Mohamed Helal,Heba A Fayyaz,Mohamed Ismail Nounou
出处
期刊:Pharmaceutical patent analyst
[Newlands Press Ltd]
日期:2019-07-01
卷期号:8 (4): 139-161
被引量:16
标识
DOI:10.4155/ppa-2019-0011
摘要
Continuous manufacturing (CM) has the potential to provide pharmaceutical products with better quality, improved yield and with reduced cost and time. Moreover, ease of scale-up, small manufacturing footprint and on-line/in-line monitoring and control of the process are other merits for CM. Regulating authorities are supporting the adoption of CM by pharmaceutical manufacturers through issuing proper guidelines. However, implementation of this technology in pharmaceutical industry is encountered by a number of challenges regarding the process development and quality assurance. This article provides a background on the implementation of CM in pharmaceutical industry, literature survey of the most recent state-of-the-art technologies and critically discussing the encountered challenges and its future prospective in pharmaceutical industry.
科研通智能强力驱动
Strongly Powered by AbleSci AI